Warfarin replacements: Good for patients, challenging for laboratories

Clinical Chemistry

Volumn 59, Issue 5, 2013, Pages 732-734

  Eby, Charles S ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN; DABIGATRAN ETEXILATE; HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; LABORATORY TEST; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION TESTS; HUMANS; LABORATORIES; MORPHOLINES; THIOPHENES;

EID: 84876949192     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.203174     Document Type: Editorial

References (11)

1. Baumann Kreuziger LM, Morton CT, Dries DJ. New anticoagulants: a concise review. J Trauma Acute Care Surg 2012;73:983-92.
2. Maan A, Padmanabhan R, Shaikh AY, Mansour M, Ruskin JN, Heist EK. Newer anticoagulants in cardiovascular disease: a systematic review of the literature. Cardiol Rev 2012;20:209-21.
3. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 2013;59:807-14.
4. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 2012;46:1627-36.
5. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97.
6. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8.
7. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;130:956-66.
8. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9.
9. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
10. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32:183-7.
11. Eby, C. Novel anticoagulants and laboratory testing. Int J Lab Hematol 2013;35:262-8.